{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:08:29Z","timestamp":1773212909231,"version":"3.50.1"},"reference-count":50,"publisher":"Japan Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1507\/endocrj.ej13-0123","type":"journal-article","created":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T23:06:15Z","timestamp":1378508775000},"page":"1261-1268","source":"Crossref","is-referenced-by-count":5,"title":["Female sex hormones are associated with the reduction of serum sodium and hypertension complications in patients with aldosterone-producing adenoma"],"prefix":"10.1507","volume":"60","author":[{"given":"Zhao-Hui","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Xiao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-qing","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Qing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Ling","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Zhi Ou","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Jun","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Hua","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Juan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Ming","family":"Ba","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Tao","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ming","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, et al. (2003) Primary aldosteronism and hypertensive disease. <i>Hypertens<\/i> 42: 161-165.","DOI":"10.1161\/01.HYP.0000079505.25750.11"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Young WF Jr. (2003) Minireview: Primary aldosteronism&mdash;changing concepts in diagnosis and treatment. <i>Endocrinology <\/i>144: 2208-2213.<b> <\/b>","DOI":"10.1210\/en.2003-0279"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Fogari R, Preti P, Zoppi A, Rinaldi A, Fogari E, et al. (2007) Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone\/renin ratio above 25 as a screening test. <i>Hypertens Res <\/i>30: 111-117.","DOI":"10.1291\/hypres.30.111"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ye D, Dong F, Lu X, Zhang Z, Feng Y, et al. (2012) Analysis of various etiologies of hypertension in patients hospitalized in the endocrinology division.<i>Endocrine <\/i>42: 174-181.","DOI":"10.1007\/s12020-011-9588-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, et al. (2008) Primary aldosteronism: cardiovascular, renal and metabolic implications. <i>Trends Endocrinol Metab <\/i>19: 88-90.","DOI":"10.1016\/j.tem.2008.01.006"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, et al. (2008) Cardiovascular outcomes in patients with primary aldosteronism after treatment.<i> Arch Intern Med <\/i>168: 80-85.","DOI":"10.1001\/archinternmed.2007.33"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Quinkler M, Born-Frontsberg E, Fourkiotis VG (2010) Comorbidities in primary aldosteronism. <i>Horm Metab Res <\/i>42: 429-434.","DOI":"10.1055\/s-0029-1243257"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, et al. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. <i>J Am Coll Cardiol<\/i> 45: 1243-1248.","DOI":"10.1016\/j.jacc.2005.01.015"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, et al.; Participants of the German Conn&rsquo;s Registry (2009) Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn&rsquo;s Registry. <i>J Clin Endocrinol Metab<\/i> 94: 1125-1130.<b> <\/b>","DOI":"10.1210\/jc.2008-2116"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Born-Frontsberg E, Reincke M, Beuschlein F, Quinkler M (2009) Participants of German Conn&rsquo;s Registry Tumor size of Conn&rsquo;s adenoma and comorbidities. <i>Horm Metab Res<\/i> 41: 785-788.","DOI":"10.1055\/s-0029-1224200"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sukor N (2012) Primary aldosteronism: from bench to bedside. <i>Endocrine<\/i> 41: 31-39.","DOI":"10.1007\/s12020-011-9553-3"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Colyewright M, Reckelhoff JF, Ouyang P (2008) Menopause and hypertension: an age-old debate. <i>Hypertension<\/i> 51: 952-959.","DOI":"10.1161\/HYPERTENSIONAHA.107.105742"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Reckelhoff JF (2010) Maric CSex and gender differences in cardiovascular-renal physiology and pathophysiology. <i>Steroids <\/i>75: 745-746.","DOI":"10.1016\/j.steroids.2010.05.020"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Rosano GM, Vitale C, Marazzi G, Volterrani M (2007) Menopause and cardiovascular disease: the evidence. <i>Climacteric <\/i>10: 19-24.","DOI":"10.1080\/13697130601114917"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Wake R, Yoshiyama M (2009) Gender differences in ischemic heart disease. <i>Recent Pat Cardiovasc Drug Discov <\/i>4: 234-240.","DOI":"10.2174\/157489009789152249"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Silbiger S, Neugarten J (2008) Gender and human chronic renal disease. <i>Gend Med<\/i> 5: S3-S10.","DOI":"10.1016\/j.genm.2008.03.002"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yang, XP, Reckelhoff JF (2011) Estrogen hormonal replacement therapy and cardiovascular disease. <i>Curr Opin Nephrol Hypertens <\/i>20: 133-138.","DOI":"10.1097\/MNH.0b013e3283431921"},{"key":"18","unstructured":"18. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, et al.; Women&rsquo;s Health Initiative Investigators (2003) Estrogen plus progestin and the risk of coronary heart disease. <i>N Engl J Med <\/i>349: 523-534."},{"key":"19","unstructured":"19. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, et al.; HERS Research Group (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II).<i> JAMA <\/i>288: 58-66."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J (2004) Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. <i>J Hypertens <\/i>22: 377-381.","DOI":"10.1097\/00004872-200402000-00023"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, et al. (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. <i>J Clin Endocrinol Metab<\/i> 89: 1045-1050.","DOI":"10.1210\/jc.2003-031337"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, et al. (1999) 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization.<i> Clin Exp Hypertens<\/i> 21: 1009-1060.","DOI":"10.3109\/10641969909061028"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Blacher J, Asmar R, Djane S, London GM, Safar ME (1999) Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. <i>Hypertension <\/i>33: 1111-1117.","DOI":"10.1161\/01.HYP.33.5.1111"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sechi LA, Kronenberg F, De Carli S, Falleti E, Zingaro L, et al. (1997) Association of serum lipoprotein (a) levels and apolipoprotein (a) size polymorphism with target-organ damage in arterial hypertension. <i>JAMA<\/i> 277: 1689-1695.","DOI":"10.1001\/jama.1997.03540450045033"},{"key":"25","unstructured":"25. Sechi LA, Zingaro L, Catena C, De Marchi S (2000) Increased fibrinogen levels and hemostatic abnormalities in patients with arteriolar nephrosclerosis: association with cardiovascular events. <i>Thromb Haemost <\/i>84: 565-557."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Yang D, Haines CJ, Pan P (2008) Menopausal symptoms in mid-life women in southern China. <i>Climacteric <\/i>11: 329-936.","DOI":"10.1080\/13697130802239075"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Brent GA (2008) Clinical practice. Graves&rsquo; disease. <i>N Engl J Med<\/i> 358: 2594-2605.","DOI":"10.1056\/NEJMcp0801880"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, Rose NR (2005) Autoimmune hypophysitis.<i> Endocr Rev <\/i>26: 599-614.","DOI":"10.1210\/er.2004-0011"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Lafranchi SH, Snyder DB, Sesser DE, Skeels MR, Singh N, et al. (2003) Follow-up of newborns with elevated screening T4 concentrations. <i>J Pediatr <\/i>143: 296-301.","DOI":"10.1067\/S0022-3476(03)00184-7"},{"key":"30","unstructured":"30. Schirpenbach C, Segmiller F, Diederich S, Hahner S, Lorenz R, et al. (2009) The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry. <i>Dtsch Arztebl Int <\/i>106: 305-311."},{"key":"31","unstructured":"31. Tang KL, Yang CH, Li LM (2011) Retroperitoneal laparoscopic operation for aldosterone-producing adenomas: a report of 205 cases. <i>Chin J Gen Pract <\/i>10: 583-585. (Article in Chinese) http:\/\/www.cqvip.com\/QK\/85925X\/201108\/38872042.html"},{"key":"32","unstructured":"32. Liu Q, Li HZ, Zhou XF, Zhou YR, Zhu WL, Zeng ZP (2006) Clinical analysis of cardiac damage in patients with primary hyperaldosteronism (PA) caused by adenoma. <i>Beijing Med J<\/i> 28: 78-80. (Article in Chinese) http:\/\/new.med.wanfangdata.com.cn\/Paper\/Detail?id=PeriodicalPaper_bjyx200602005"},{"key":"33","unstructured":"33. Zhang W, Tang ZY, Wang WQ, Ning G (2007) Prevalence of metabolic syndrome in patients with primary aldosteronism. <i>Chin J Endocrinol Metab <\/i>23 (6): 532-534. (Article in Chinese) http:\/\/www.cqvip.com\/QK\/91842X\/200706\/27738269.html"},{"key":"34","unstructured":"34. Li NF, Li HJ, Wang HM (2011) Clinical analysis of 330 patients with primary aldosteronism. <i>Chin J Endocrinol Metab <\/i>27: 752-754. (Article in Chinese) http:\/\/d.wanfangdata.com.cn\/Periodical_zhnfmdx201109013.aspx"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Arias-Loza PA, Hu K, Dienesch C, Mehlich AM, K&ouml;nig S, et al. (2007) Both estrogen receptor subtypes, &alpha; and &beta;, attenuate cardiovascular remodeling in aldosterone salt-treated rats.<i>Hypertension <\/i>50: 432-438.","DOI":"10.1161\/HYPERTENSIONAHA.106.084798"},{"key":"36","unstructured":"36. Xue BJ, Badaue-Passos D Jr., Guo F, Gomez-Sanchez CE, Hay M, et al. (2009) Sex differences and central protective effect of 17&beta;-estradiol in the development of aldosterone\/NaCl-induced hypertension. <i>Am J Physiol Heart Circ Physiol <\/i>296: H1577-H1585."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, et al. (2004) Relations of serum aldosterone to cardiac structure: Gender-related differences in the Framingham Heart Study. <i>Hypertension<\/i> 43: 957-962.","DOI":"10.1161\/01.HYP.0000124251.06056.8e"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Berardelli R, Karamouzis I, D&rsquo;Angelo V, Zichi C, Fussotto B, et al. (2013) Role of mineralocorticoid receptors on the hypothalamus-pituitary-adrenal axis in humans<i>. <\/i><i>Endocrine <\/i>43: 51-58.","DOI":"10.1007\/s12020-012-9750-8"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, et al. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. <i>J Am Coll Cardiol<\/i> 45: 1243-1248.","DOI":"10.1016\/j.jacc.2005.01.015"},{"key":"40","unstructured":"40. Dahl LK, Love RA (1954) Evidence for relationship between sodium (chloride) intake and human essential hypertension.<i> AMA Arch Intern Med <\/i>94: 525-531."},{"key":"41","unstructured":"41. Sasaki N (1964) The relationship of salt intake to hypertension in the Japanese.<i> Geriatrics <\/i>19: 735-744."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Swaye PS, Gifford Jr RW, Berrettoni JN (1972) Dietary salt and essential hypertension. <i>Am J Cardiol <\/i>29: 33-38.","DOI":"10.1016\/0002-9149(72)90412-2"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Stamler J (1997) The INTERSALT study: background, methods, findings, and implications. <i>Am J Clin Nutr <\/i>65: 626S-642S.","DOI":"10.1093\/ajcn\/65.2.626S"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. He FJ, MacGregor GA (2002) Effect of modest salt reduction on blood pressure: meta analysis of randomized trials. Implication for public health.<i> J Hum Hypertens<\/i> 16: 761-770.","DOI":"10.1038\/sj.jhh.1001459"},{"key":"45","unstructured":"45. Stachenfeld NS, Taylor HS (2009) Sex hormone effects on body fluid and sodium regulation in women with and without exercise-associated hyponatre<i>m<\/i>ia. <i>J Appl Physiol <\/i>107: 864-872."},{"key":"46","unstructured":"46. Stachenfeld NS, Keefe DL (2002) Estrogen effects on osmotic regulation of AVP and fluid balance. A<i>m J Physiol Endrocrinol Meta<\/i>b283: E711-E721."},{"key":"47","unstructured":"47. Fraser CL, Sarnacki P (1989) Na+-K+-ATPase pump funciton in rat brain synaptosomes is different in males and females. <i>Am J Physiol<\/i> 257: E284-E289."},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Letavernier E, Peyrard S, Amar L, Zinzindohou&eacute; F, Fiquet B, et al. (2008) Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or withoutunilateral adenoma.<i> J Hypertens <\/i>26: 1816-1823.","DOI":"10.1097\/HJH.0b013e3283060f0c"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Zarnegar R, Young WF Jr, Lee J, Sweet MP, Kebebew E, et al. (2008) The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. <i>Ann Surg <\/i>247: 511-518.","DOI":"10.1097\/SLA.0b013e318165c075"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, et al. (2008) Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. <i>Hypertension<\/i> 51: 1366-1371.","DOI":"10.1161\/HYPERTENSIONAHA.108.111369"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/11\/60_EJ13-0123\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:39:07Z","timestamp":1618295947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/11\/60_EJ13-0123\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej13-0123","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}